Comments on: Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients

Comments on: Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients https://www.novumpr.nl/2016/10/20/gilead-announces-svr12-rates-from-four-phase-3-studies-of-a-once-daily-fixed-dose-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-treatment-naive-and-treatment-experienced-genotype-1-6-chr/?utm_source=rss&utm_medium=rss&utm_campaign=gilead-announces-svr12-rates-from-four-phase-3-studies-of-a-once-daily-fixed-dose-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-treatment-naive-and-treatment-experienced-genotype-1-6-chr NovumPR press releases Thu, 20 Oct 2016 16:15:32 +0000 hourly 1 https://wordpress.org/?v=6.8.3